This, together with the efficiency of the E6 antibody in mediating the degradation of the cytoplasmic TDP43, might eventually result in a stronger therapeutic effect in ALS/FTLD mouse models. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.